Literature DB >> 2327077

Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.

W E Robinson1, D C Montefiori, W M Mitchell.   

Abstract

In this study it is demonstrated that complement-mediated antibody-dependent enhancement (C'-ADE) of HIV-1 infection in vitro is blocked by murine monoclonal antibodies to CD4 and complement receptor type 2 (CR2) while HIV-1 infection in the absence of C'-ADE is blocked by anti-CD4 but not anti-CR2 monoclonal antibodies. The anti-CR2 murine monoclonal antibody, OKB7, blocked C'-ADE of HIV-1 infection at concentrations greater than 1 microgram/ml. The anti-CD4 monoclonal antibody, OKT4a, but not OKT4f blocked C'-ADE at concentrations greater than 0.06 microgram/ml. HIV-1 infections were quantitated by cytopathic effect, indirect immunofluorescence, and reverse transcriptase release. It appears from these in vitro studies that C'-ADE of HIV-1 infection requires both CD4 and complement receptors while HIV-1 infection in the absence of antibody and complement requires only CD4.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327077     DOI: 10.1016/0042-6822(90)90449-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

2.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 3.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Authors:  Johannes S Gach; David Venzon; Monica Vaccari; Brandon F Keele; Genoveffa Franchini; Donald N Forthal
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

5.  Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; D Lake; Y Masuho; W M Mitchell; E M Hersh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).

Authors:  D C Montefiori; K Stewart; J M Ahearn; J Zhou; J Zhou
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Feline CD4 molecules expressed on feline non-lymphoid cell lines are not enough for productive infection of highly lymphotropic feline immunodeficiency virus isolates.

Authors:  J Norimine; T Miyazawa; Y Kawaguchi; K Tomonaga; Y S Shin; T Toyosaki; M Kohmoto; M Niikura; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

Authors:  C Osiowy; D Horne; R Anderson
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.